As the incidence of asthma and allergic rhinitis rises, the market for products to treat these diseases are expected to show strong growth. This Frost & Sullivan report analyzes the markets for a full range of product to treat asthma and rhinitis, including anti-inflammatory agents, mast cell mediators, inhaled bronchodilators, methylxanthines and antihistamines. It examines factors driving and restraining growth in eight European regional markets, providing a detailed road map of the industry's future.
